Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06526793
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-03
Brief Title:
AZD0486 as Monotherapy in Participants With RelapsedRefractory RR B-cell NHL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Modular Phase 2 Single-arm Multicenter Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory RR B-cell Non-Hodgkin Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 global multi-center open-label study to assess the efficacy safety and tolerability of AZD0486 monotherapy in adult participants with relapsedrefractory B-cell non-Hodgkin lymphoma NHL who have received at least two prior lines of therapies The study has 2 Modules Module 1 for FL and Module 2 for DLBCL
Detailed Description:
This is a modular Phase II multicenter single-arm open-label study to evaluate the efficacy and safety of AZD0486 monotherapy administered as an intravenous IV infusion in participants with relapsed or refractory B-NHL The purpose of this study is to determine the efficacy and safety of AZD0486 administered at the RP2D in adults 18 to 80 years of age with relapsed or refractory B-NHL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None